Overview
- UnitedHealth shares reached a new 52‑week high of $417.58 on June 26, 2026, a run that leaves the stock about 28% higher year to date and roughly 37% above its level a year ago.
- Investors credit Optum — the company’s data, pharmacy, and care-delivery businesses — and steadier medical‑cost trends for the rebound because those items have smoothed earnings and cut reliance on insurance‑cycle swings.
- Wall Street’s consensus is a Moderate Buy based on 19 buy, 3 hold and 1 sell ratings with an average price target near $407, a level that sits slightly below the recent share price and reflects divided views on valuation.
- Markets are now focused on UnitedHealth’s Q2 earnings, which the company will report on July 16, 2026, where analysts expect about $4.84 of diluted EPS and will watch Optum margins and medical‑cost trends for confirmation of the recovery.
- Ongoing governance and legal items pose downside risk because CDC nominee Erica Schwartz plans to resign from UnitedHealth if confirmed and the Luigi Mangione court case linked to the company remains active, any of which could sway investor sentiment and operations.